Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7779]

$ASH 2012: Ibrutinib promotes high response rate in treatment naïve and relapsed or refractory chronic lymphocytic leukaemia$

ASH 2012: Ibrutinib promotes high response rate in treatment naïve and relapsed or refractory chronic lymphocytic...

SABCS 2012: Phase III trial did not show superiority of eribulin compared with capecitabine in metastatic breast cancer

SABCS 2012: Phase III trial did not show superiority of eribulin compared with capecitabine in metastatic breast...

SABCS 2012: Breast cancer genome sequencing identified HER2 mutations as targets for drug treatment

SABCS 2012: Breast cancer genome sequencing identified HER2 mutations as targets for drug treatment

SABCS 2012: Adjuvant bevacizumab does not improve invasive disease-free survival in triple-negative breast cancer

SABCS 2012: Adjuvant bevacizumab does not improve invasive disease-free survival in triple-negative breast cancer

SABCS 2012: Extending adjuvant trastuzumab treatment time provided no additional benefit

SABCS 2012: Extending adjuvant trastuzumab treatment time provided no additional benefit

Women with higher carotenoid levels have reduced risk of breast cancer

Women with higher carotenoid levels have reduced risk of breast cancer

SABCS 2012: HDAC inhibitors sensitised triple-negative breast cancer cells to PARP inhibition and cisplatin treatment

SABCS 2012: HDAC inhibitors sensitised triple-negative breast cancer cells to PARP inhibition and cisplatin...

SABCS 2012: Young women with breast cancer were more likely than older women to respond to neoadjuvant chemotherapy

SABCS 2012: Young women with breast cancer were more likely than older women to respond to neoadjuvant chemotherapy

SABCS 2012: Study confirms fewer, bigger doses of radiotherapy benefit cancer patients

SABCS 2012: Study confirms fewer, bigger doses of radiotherapy benefit cancer patients

SABCS 2012: Extending duration of adjuvant tamoxifen treatment to 10 years reduced risk for late breast cancer recurrence, improved survival

SABCS 2012: Extending duration of adjuvant tamoxifen treatment to 10 years reduced risk for late breast cancer...

More from ecancer